Zobrazeno 51 - 60
of 107
pro vyhledávání: '"Daniel S Chen"'
Autor:
Hartmut Koeppen, Dafeng Chen, Daniel S. Chen, Kathy D. Miller, James D. Reimann, Virginia K. Langmuir, Hope S. Rugo, Adrian M. Jubb, Melody A. Cobleigh, Kenneth J. Hillan, Adrian L. Harris, Maike Schmidt
Publikováno v:
Clinical Cancer Research; Vol 17
Purpose: The addition of bevacizumab to cytotoxic chemotherapy has demonstrated a progression-free survival (PFS) benefit in the first-line and second-line treatment of advanced or metastatic breast cancer (MBC). However, the addition of bevacizumab
Autor:
Alessandra Castiglioni, Sanjeev Mariathasan, Ira Mellman, Edward E. Kadel, Kobe C. Yuen, Jillian L. Astarita, Suchit Jhunjhunwala, Rafael Cubas, Hartmut Koeppen, Yagai Yang, Shannon J. Turley, Yulei Wang, Richard Bourgon, Priti S. Hegde, Dorothee Nickles, Thomas Powles, Daniel S. Chen, Yasin Senbabaoglu
Publikováno v:
Cancer Research. 78:2979-2979
Checkpoint inhibitor blockade can result in robust and durable anti-tumor responses in various cancers, including metastatic urothelial cancer (mUC). However, these responses only occur in a subset of patients. Identifying determinants of response an
Autor:
György Losonczy, David R. Spigel, Weilan Ye, Thomas Ervin, Fabrice Barlesi, Ina Rhee, Eric Wakshull, Maria Anderson, E. Juhasz, Priti S. Hegde, Joachim von Pawel, Martin Reck, Ilsung Chang, Daniel S. Chen, Bruce McCall
Publikováno v:
The Oncologist
Lessons LearnedThe lack of efficacy associated with anti-EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non-small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highli
Autor:
Sun Young Rha, Mahtab Marker, Noah Berkowitz, Poulam M. Patel, Thomas W. Flaig, Carlos H. Barrios, Jennifer J. Knox, Thomas Cosgriff, K. Pittman, Robert J. Motzer, Vichien Srimuninnimit, Daniel S. Chen, Ray D. Page, J. T. Beck, L. Geoffrois, Tae Min Kim, Sunil Yadav, FY Cheung, Julie Niolat, Roberto Sabbatini
Publikováno v:
Annals of Oncology
Background RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). T
Autor:
Zachary Boyd, Rin Nakamura, Gregg Fine, Thomas Powles, Priti S. Hegde, Xiaodong Shen, Daniel P. Petrylak, Nicholas J. Vogelzang, Daniel S. Chen, Teiko Sumiyoshi, Christina Rabe, Mitchell Denker, Marcin Kowanetz, Siew-leng Melinda Teng, Qun J Wu, Yuanyuan Xiao, Yohann Loriot
Publikováno v:
Journal for Immunotherapy of Cancer
Treatment options for metastatic urothelial bladder cancer (UBC) are limited. Mutational complexity is known to be high in UBC and may correlate with increased immunogenicity. MPDL3280A, a human PD-L1 monoclonal antibody containing an engineered Fc-d
Publikováno v:
Experimental Cell Research
Mouse hepatitis virus (MHV), a murine coronavirus, utilizes murine carcinoembryonic antigens as receptors. The events that follow virus-receptor binding and eventually lead to virus entry are poorly understood. We studied the possible effects of MHV
Autor:
Daniel S. Chen, Zach Boyd, Gregg Fine, David F. McDermott, Ning Leng, Dorothee Nickles, Jennifer Doss, Priti S. Hegde, Thomas Powles, Berard Escudier, Christina Schiff, Michael B. Atkins, Robert J. Motzer, Mahrukh Huseni, Shruthi Sampath, Brian I. Rini
Publikováno v:
Cancer Research. 77:CT081-CT081
Background: The addition of bevacizumab (bev) to atezolizumab (atezo) has demonstrated enhanced anti-tumor immune responses in pts with solid tumors (Wallin 2016). In IMmotion150 (NCT01984242), a phase II trial that compared atezo+/-bev vs sunitinib
Autor:
Yu-Chi Hou, Yuan-Man Hsu, Chiung-Hung Chang, Bi Yu, Chiu-Hsian Su, Yueh-Sheng Chen, Daniel S. Chen
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 8, p e105362 (2014)
PLoS ONE, Vol 9, Iss 8, p e105362 (2014)
Salmonella, a common zoonotic pathogen, causes gastroenteritis in both humans and animals. Traditional Chinese Medicine (TCM) has been used to improve gastrointestinal dysfunction and to modify the immune response to inflammation for centuries. This
Autor:
Joseph Paul Eder, Daniel S. Chen, Fadi Braiteh, Priti S. Hegde, Xiaodong Shen, Daniel P. Petrylak, Yohann Loriot, Joaquim Bellmunt, Zachary Boyd, Cristina Cruz, Thomas Powles, Gregg Fine, Siew-leng Melinda Teng, Howard A. Burris, Nicholas J. Vogelzang
Publikováno v:
Nature. 515(7528)
There have been no major advances for the treatment of metastatic urothelial bladder cancer (UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient outcomes, especially for those in whom chemotherapy is not effective or is poo
Autor:
Jonathan Polikoff, J. von Pawel, Manuel Cobo Dols, Achim Rittmeyer, Marcin Kowanetz, K. Park, Daniel S. Chen, Pei He, Daniel Waterkamp, Diego Cortinovis, Marcus Ballinger, Fabrice Barlesi, Alan Sandler, Shirish M. Gadgeel, Fortunato Ciardiello, Carlos H. Barrios, Joseph W. Leach, Toyoaki Hida, David R. Gandara, Dariusz M. Kowalski
Publikováno v:
Annals of Oncology. 27:vi581